(Press-News.org) PHILADELPHIA -- Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs, according to a review published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
"The term epigenetics refers to the study of cellular changes in gene expression that are heritably transmitted during cell replication," said Michele Maio, MD, PhD, chair of medical oncology and immunotherapy, Ospedale Santa Maria alle Scotte, Istituto Toscano Tumori, in Siena, Italy. "Epigenetic modifications do not involve structural alterations of the DNA sequence, as in the case of genetic mutations. Instead, they are chemical modifications of the DNA structure at specific sites that lead to the 'hypermethylation' or 'hypomethylation' of specific DNA elements that regulate gene expression.
"Cancer was the first human disease in which epigenetic modifications were found to play an important role in development and progression," explained Maio.
Maio said that his team recently provided comprehensive evidence demonstrating that epigenetic changes play a major role in downregulating or shutting off the expression of certain cell-surface molecules that play a crucial role in the efficient recognition and elimination of cancer cells by the immune system. As a result, cancer cells become "invisible" to the immune system, which cannot eliminate them from the body. "Based on experimental evidence from our studies, we expect that epigenetic drugs could be efficiently utilized to restore the expression of these molecules, thus rendering cancer cells again 'visible' to the immune system to effectively eliminate them," Maio said.
In addition, epigenetic drugs can also act by lowering or eliminating specific subsets of immune cells such as myeloid-derived suppressor cells, which have been shown to facilitate tumor growth, Maio explained.
Maio and colleagues delineated in this review article evidence from preclinical studies that provides the rationale behind combining epigenetic therapies with immunotherapies such as interleukin-2 therapy, adoptive T-cell transfer, and immune checkpoint inhibitors, among others.
"The data we generated in a mouse model demonstrated that combining epigenetic drugs, such as the DNA methyltransferase inhibitors (DNMTi) 5-aza-2?-deoxycytidine and guadecitabine, with immunomodulating antibodies that target CTLA-4 or the PD-1/PDL-1 immune checkpoint improves the therapeutic efficacy of each drug utilized alone. Based on this experimental evidence, we have now designed a phase Ib clinical trial in which guadecitabine and the anti-CTLA-4 immunomodulating monoclonal antibody ipilimumab will be given in sequence as first-line or second-line therapy to metastatic melanoma patients; this study is sponsored by the NIBIT Foundation and partially supported by Astex Pharmaceuticals," Maio added.
The review article also provides a comprehensive overview of all ongoing clinical trials that are evaluating combinations of epigenetic drugs and immunotherapy against many cancer types, including leukemias, metastatic melanoma, metastatic kidney cancer, peripheral neuroectodermal tumors, non-small cell lung cancer, and metastatic colorectal cancer.
"The major and well-known side effect of DNMTi is myelotoxicity, which poses limits to their dosage and length of administration, and needs to be carefully monitored in the course of treatment," Maio cautioned. "Along this line, combination regimens with these epigenetic drugs have to be carefully reasoned and evaluated for potential additive myelotoxicity," he added.
"Like the tango, which takes two and in perfect syntony, the most successful results with cancer immunotherapies will require a perfect interaction between patients' immune systems and their cancer cells. In light of their powerful immunomodulating potential, epigenetic drugs are seemingly the best 'partner drugs' to emerging immunotherapies to achieve this perfect interaction, and will most likely provide additional clinical benefit to cancer patients treated with state-of-the-art immunotherapeutic drugs," Maio said.
INFORMATION:
Maio was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro and the Italian Ministry of Health. He is a consultant/advisory board member for AstraZeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline PLC, MedImmune, and Roche. He is a co-inventor on a patent-pending application for DNA hypomethylating agents for cancer therapy, which is partially based on findings included in this article.
Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 101 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 25 conferences and educational workshops, the largest of which is the AACR Annual Meeting with nearly 19,300 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.
Video games are not adequately rated for tobacco content, according to a new UC San Francisco study that found video gamers are being widely exposed to tobacco imagery.
The researchers concluded that a national ratings board set up more than 20 years ago is not a reliable source for learning whether video games contain tobacco imagery.
The study will be published online September 14 in Tobacco Control.
"Parents should stop relying on the ratings to screen for tobacco use in buying video games for their kids," said first author Susan Forsyth, a PhD candidate at ...
Working shifts of 16 to 24 hours in length is linked to a 60% heightened risk of injury and illness among emergency services (EMS) clinicians, compared to shifts of 8-12 hours, finds research published online in Occupational & Environmental Medicine.
This risk rises in tandem with shift length, the findings show.
The nature of the job requires physical strength to lift and move patients, clear mental focus to deliver medical care in uniquely stressful and often chaotic situations, and sufficient alertness to drive safely, say the researchers.
Yet EMS clinicians often ...
The 3M software program, increasingly used to make payments to US hospitals based on readmission rates, doesn't clearly distinguish differences in care quality--one of the key factors involved in readmission--between readmissions that are preventable and those that aren't, suggests research published online in BMJ Quality and Safety.
The Centers for Medicare and Medicaid Services (CMS) posts data on 30 day readmissions for three common causes of hospital admissions: heart attack; heart failure; and pneumonia.
Hospitals with high rates of readmissions are penalised ...
A study of 350,000 patients with type 2 diabetes shows that those with poor blood sugar control have 50% higher risk of being admitted to hospital in future for dementia as those with good control. The research, which suggests improving blood sugar control could prevent many cases of dementia, is by Dr Aidin Rawshani, National Diabetes Register and Institute of Medicine, Gothenburg, Sweden, and colleagues, and is presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm.
Evidence is growing that diabetes increases ...
New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Stockholm shows that diabetic women are more at risk than diabetic men of having a heart attack and other complications as they age. The study is by Dr Giuseppe Seghieri, Regional Health Agency, Florence, Italy, and colleagues.
Previous research has revealed that diabetic women have a higher risk of cardiovascular events than diabetic men, when compared with the respective non-diabetic counterparts. However, it is unclear when this risk begins or how long it ...
A systematic review and meta-analysis of 19 studies containing almost 11 million patients shows that diabetic women are around 40% more likely to suffer acute coronary syndromes (heart attack or angina) than diabetic men. The study is by Dr Xue Dong, the Affiliated ZhongDa Hospital of Southeast University, Nanjing, China, and colleagues, and is presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm.
Diabetes is a strong risk factor for acute coronary syndrome, yet whether diabetes confers the same excess risk ...
In 2013, England performed better than average on a variety of key health outcomes compared with 18 other high-income countries in the European Union [1], and Australia, Canada, Norway, and the USA (EU15+), according to new research published in The Lancet.
However, the findings also reveal the impact of substantial health disparities within English regions, the significant toll of chronic disabling conditions, and the importance of tackling preventable diseases. It is likely that around 40% of NHS workload is due to potentially preventable risk factors.
Using data ...
An international panel of experts applied the RAND/UCLA Appropriateness Method to develop criteria for use of peripherally inserted central catheters (PICCs). The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) is published as a supplement in Annals of Internal Medicine.
Use of PICCs has become popular for venous access in hospital settings but their use can result in important complications, such as thrombosis and infection. In addition, a growing number of studies suggest substantial variation and potentially inappropriate use of PICCs in hospitalized ...
Cost of Sustaining a Patient-Centered Medical Home More than $100,000 per Full Time Physician Annually
With primary care practices in the United States aggressively shifting to the patient-centered medical home model of care, researchers examine the costs to deliver PCMH functions and find even partial implementation costs approximately $105,000 per full time equivalent provider annually. Using a PCMH cost dimensions tool, researchers assessed costs associated with activities uniquely required to maintain PCMH functions at a diverse group of 20 primary care practices in ...
BOSTON--September 14, 2015--Researchers from Harvard-affiliated Hebrew SeniorLife Institute for Aging Research (IFAR), in collaboration with scientists from a number of international institutes, have identified a genetic variant regulating a gene responsible for bone mineral density and fracture risk. Findings from this study--funded in part by grants from the National Institutes of Health (NIH)--are published in the journal Nature and could lead to interventions that may prevent fractures in older adults.
Osteoporosis, a word meaning "porous bone," is a disease that ...
